Introduction
============

Hearing loss, the most common sensory deficit, affects approximately 1/500 newborns. Most congenital and childhood-onset cases are nonsyndromic (70%) and of monogenic origin, with autosomal-recessive inheritance accounting for about 80%. Approximately 20% of patients have autosomal-dominantly inherited forms (ADNSHL). More than 60 ADNSHL loci have been reported. Targeted next-generation sequencing (NGS) of the known deafness genes' exons ("gene panels") is a powerful tool to reveal the disease-causing mutations in patients with hearing loss.

Different mutations in the same Mendelian disease genes may cause distinct---allelic--- disorders. They may differ not only clinically but also in their mode of inheritance. Regarding the latter phenomenon, several genes implicated in inherited hearing loss, a condition of extensive genetic heterogeneity, have been associated with both autosomal-recessive and -dominant forms, e.g., *GJB2*, *MYO7A*, *TMC1*, *TECTA*, *MYO6*, and *TBC1D24.*^[@bib1]^ Here, we report cosegregation of a C-terminally located heterozygous nonsense mutation in *PTPRQ*, a gene implicated in autosomal-recessive deafness, with autosomal-dominant progressive hearing loss in a large family. We propose a location-dependent "shift" of the inheritance mode, possibly due to escape of the mutant transcript from nonsense-mediated decay (NMD).

Materials and methods
=====================

Patients
--------

Samples were obtained with written informed consent. Clinical investigations were conducted according to the Declaration of Helsinki, and the study was approved by the institutional review boards of the ethics committees of the University Hospital of Dresden and the University Hospital of Cologne.

Clinical examinations
---------------------

The members of the investigated four-generation Caucasian family from Germany were assessed with regard to their history of hearing ([Supplementary Table S1](#sup1){ref-type="supplementary-material"} online). Adult family members III:1, III:2, III:4, and II:2 were investigated by pure-tone audiometry. In children (the index patient, IV:2 and his brother IV:3), pedaudiological investigation included both brain stem electric response audiometry and subjective audiometry. Hearing loss was classified as mild (20--40 dB), moderate (41--60 dB), severe (61--90 dB), or profound (\>90 dB) ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Next-generation sequencing of a deafness gene panel
---------------------------------------------------

Next-generation sequencing (NGS) of the DNA sample of the index patient, IV:2 (Figure 2a), was conducted for 66 genes (1,259 coding exons) that have been associated with nonsyndromic hearing loss and selected forms of syndromic hearing loss ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}) on a MiSeq system (Illumina, San Diego, CA), as previously described.^[@bib2]^ In brief, sheared DNA was ligated to barcoded adaptors for multiplexing. Exons were targeted by an in-solution customized sequence capture library (NimbleGen, Madison, WI). Amplified enriched DNA was subjected to NGS. Reads were mapped against the hg19 human reference genome using Burrows--Wheeler Aligner^[@bib3]^ and processed with SAMtools,^[@bib4]^ Picard (<http://picard.sourceforge.net>) and Genome Analysis Toolkit.^[@bib5]^ Variants were filtered against dbNSFP v2.0,^[@bib6]^ dbSNP v137, ExAC,^[@bib7]^ the Human Gene Mutation Database (HGMD Professional 2013.2),^[@bib8]^ and the Cologne Center for Genomics in-house database. The cutoff for the maximum minor allele frequency was set to 1%.^[@bib9]^ Nonsense, frameshift and canonical splice site variants were regarded as likely pathogenic. Single-nucleotide variants were assessed using SIFT,^[@bib10]^ MutationTaster,^[@bib11]^ PolyPhen-2,^[@bib12]^ AlignGVGD,^[@bib13],\ [@bib14]^ Pmut,^[@bib15]^ NNSPLICE v0.9^[@bib16]^ and NetGene2.^[@bib17],\ [@bib18]^ SeqPilot SeqNext module (v4.0.1, JSI Medical Systems, Ettenheim, Germany) was used for visualization and final assessment of single-nucleotide variants. Sequence data for *PTPRQ* (MIM 603317) were compared with the reference sequence NM_001145026.1. Schraders et al.^[@bib19]^ have proposed additional *PTPRQ* exons (Figure 3c) that are not contained in NM_001145026.1. All *PTPRQ* exons, including those described by Schraders et al. and putative additional exons from N-Scan predictions were covered by panel NGS and subsequent Sanger sequencing. Verification of the *PTPRQ* mutation c.6881G\>A (p.Trp2294\*) and segregation analyses were carried out by Sanger sequencing. The novel *PTPRQ* mutation described herein has been submitted to the Leiden Open Variation Database^[@bib20]^ (<http://databases.lovd.nl/shared/genes/ptprq>).

Genome-wide linkage analysis
----------------------------

DNA was extracted from peripheral blood samples using standard methods. DNA samples of 11 individuals (seven affected individuals from four generations, including the young proband with occasional "borderline" audiometry results, IV:3; [Supplementary Table S1](#sup1){ref-type="supplementary-material"}) were subjected to genome-wide linkage analysis using the Infinium CoreExome-24 v1.1 BeadChip (Illumina) according to the manufacturer's protocol. Subsequent data handling was performed using the graphical user interface ALOHOMORA.^[@bib21]^ Relationship errors were identified by using the program Graphical Relationship Representation.^[@bib22]^ The program PedCheck was applied to find Mendelian errors,^[@bib23]^ and data for single-nucleotide polymorphisms (SNPs) with such errors were removed. Non-Mendelian errors were identified by using the program MERLIN^[@bib24]^ and unlikely genotypes for related samples were deleted. Linkage analysis was performed assuming autosomal-dominant inheritance, full penetrance, and a disease gene frequency of 0.0001. Multipoint logarithm of the odds (LOD) scores were calculated using the program ALLEGRO.^[@bib25]^ Haplotypes were reconstructed with ALLEGRO and presented graphically with HaploPainter.^[@bib26]^

Whole-exome sequencing
----------------------

Whole-exome sequencing (WES) was performed after enrichment with Roche/NimbleGen technology (SeqCap EZ Exome v2.0 Library) in a pool of 10 samples on an Illumina 1500 instrument in rapid mode (TruSeq Rapid SBS chemistry v1). WES data were analyzed with a focus on the mapped candidate region on chromosome 12 including *PTPRQ*, but also beyond that region ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Semiquantitative reverse-transcriptase polymerase chain reaction
----------------------------------------------------------------

Fibroblast cell lines derived from skin biopsies of a control subject and patient III:2 were established and maintained in culture at 37 °C, 5% CO~2~ in Dulbecco\'s Modified Eagle Medium supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, and 0.75 μg/ml amphotericin B. 2  ×  10^5^ fibroblasts were seeded in triplicates in a six-well plate. The following day, RNA was extracted according to the manufacturer's protocol (RNeasy Mini Kit, Qiagen, Hilden, Germany). 600 ng of fibroblast RNA was retrotranscribed using the QuantiTect Reverse Transcription Kit (Qiagen) and complementary DNA was diluted with TE^−4^ buffer to 20 ng/μl. Semiquantitative reverse-transcription polymerase chain reaction were carried out using recombinant Taq DNA Polymerase (Invitrogen, Waltham, MA, USA) in a BioRad C1000 Touch Thermal Cycler (Biorad, Hercules, CA, USA). For details regarding polymerase chain reaction conditions and primers, see [Supplementary Table S4](#sup1){ref-type="supplementary-material"}. Samples were run in a 1.5% agarose gel and visualized with a BioRad Chemidoc XRS system. Analysis was performed using ImageLab 5.2.1 (BioRad) and statistical analysis using MS Excel 2013 (Student's *t*-test).

Results
=======

Characterization of hearing loss in a four-generation ADNSHL family
-------------------------------------------------------------------

The initial pedaudiological investigation of the index patient, IV:2, at the age of 2½ years was carried out because of delayed language development. A mild to severe bilateral sensorineural hearing loss was found and bilateral conventional hearing aids were put in use. Family members carrying the *PTPRQ* mutation were found to be affected by hearing loss with variable age of onset (early childhood to third decade) and variable course, as is particularly apparent in the patient's mother, maternal grandmother, maternal great-grandmother, and great-aunt and her son ([Supplementary Table S1](#sup1){ref-type="supplementary-material"},[Figure 1](#fig1){ref-type="fig"}). Results from pedaudiologic assessment in a young male carrier of the mutation (IV:3, last audiology exam performed at the age of 4 years) fluctuated between borderline mild hearing impairment and normal hearing ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Individuals III:1, III:2, and IV:1--4 were personally examined by clinical geneticists and had normal body measurements, no specific minor anomalies, and no additional major health issues. The other affected individuals (I:2, II:2, II:3, II:5, and III:4) were reportedly otherwise healthy as well.

A novel *PTPRQ* nonsense mutation, located in a mapped chromosome 12 candidate region, cosegregates with ADNSHL
---------------------------------------------------------------------------------------------------------------

Targeted NGS of known autosomal-recessive nonsyndromic hearing loss and ADNSHL genes in the index patient (IV:2) revealed a heterozygous nonsense mutation, c.6881G\>A (p.Trp2294\*) ([Figure 2c](#fig2){ref-type="fig"}), in the last coding exon of *PTPRQ* (NM_001145026.1), encoding a type III receptor-like protein tyrosine phosphatase ([Figure 3a](#fig3){ref-type="fig"}). The p.Trp2294\* mutation, which was neither present in ExAC nor in the gnomAD, cosegregated with hearing loss in the family. Additionally, linkage analysis applying genome-wide SNP mapping revealed a single genomic region with the maximum parametric LOD score of 2.4 (when including IV:3 as affected; the LOD score is 2.1 when IV:3 is excluded from the calculation) that includes the *PTPRQ* gene (12q21.2-12q22) (Figure 2b). Following the identification of the causative mutation in *PTPRQ*, *DFNA73* (MIM 617663) was assigned as a novel locus designation for ADNSHL by OMIM.

Exclusion of secondary mutations in *PTPRQ*
-------------------------------------------

NGS and Sanger sequencing of all *PTPRQ* exons, including previously described alternatively spliced 5′ exons,^[@bib19]^ did not identify any other mutation ([Table 1](#tbl1){ref-type="table"}, [Figure 3b](#fig3){ref-type="fig"}). Furthermore, NGS of all N-SCAN--predicted potential coding regions of a putative "extended" *PTPRQ* transcript did not detect another pathogenic aberration ([Figure 3c](#fig3){ref-type="fig"}).

Assessment of variants in other genes of the mapped 12q locus
-------------------------------------------------------------

WES of the index patient identified another heterozygous nonsense variant, c.4948delA (p.Met1650\*), in the *LRRIQ1* gene, encoding a leucine-rich repeats and IQ motif containing protein, in the mapped candidate locus on chromosome 12. The c.4948delA (p.Met1650\*) variant is listed in dbSNP (rs763597988), but it is rare (one heterozygous individual annotated in the ExAC database, corresponding to a minor allele frequency of 0.0008%). It was present in heterozygous state in two individuals with normal hearing, the youngest sibling (IV:4) of the index patient and his oldest brother (IV:1), and in their father (III:1). Patient III:1 was not aware of his mild hearing loss affecting the high frequencies, which was accidentally diagnosed by us in the course of the audiologic characterization of the family. It was not found in the patient's mother or her affected relatives. The localization of *LRRIQ1* in the mapped candidate locus was thus coincidental and did not reflect linkage with the phenotype in the index patient's mother's family. However, it cannot be excluded that it contributes to or even causes the mild hearing loss in the index patient's father, and that hearing impairment might manifest in the two healthy carriers of the *LRRIQ1* variant at an older age.

The WES analysis did not reveal clearly pathogenic variants in known deafness genes (apart from *PTPRQ*) or in potential candidate genes, particularly not in the chromosome 12 region identified by linkage analysis ([Table 1](#tbl1){ref-type="table"}, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Two heterozygous variants were identified in two other genes from the mapped 12q region, *SYT1* and *TMTC2*. Both variants have allele frequencies in the general population above the threshold for autosomal-dominant mutations, and homozygous occurrence in healthy individuals has been documented for both (ExAC database).

*PTPRQ* transcripts harboring the c.6881G\>A variant do not undergo NMD
-----------------------------------------------------------------------

Due to the low expression of *PTPRQ* in whole blood samples, we quantified its expression in a patient-derived fibroblast cell line and compared it with a control ([Figure 4a](#fig4){ref-type="fig"}). Quantitative analysis for an N-terminal (encompassing exon 2) and a C-terminal *PTPRQ* (encompassing exon 45) region showed no differential expression between the cell lines. This demonstrates that the mutated allele escapes NMD and supports the hypothesis that a truncated PTPRQ protein is produced.

Discussion
==========

Biallelic *PTPRQ* mutations have been reported to cause nonsyndromic autosomal-recessive, but not autosomal-dominant, deafness with vestibular dysfunction (*DFNB84A*, MIM 613391).^[@bib19]^ Here, we report the most C-terminally located *PTPRQ* mutation to date, c.6881G\>A (p.Trp2294\*) in the gene's last exon, exon 45, cosegregating with ADNSHL in a large German family.

The mammalian NMD surveillance system cannot differentiate between nonsense mutations in the penultimate exon located less than \~55 bp from the final intron or in the last exon and natural stop codons in the last exon.^[@bib27]^ In contrast to recessive *PTPRQ* mutations, which have been proposed to cause *DFNB84A* via a loss-of-function mechanism,^[@bib28]^ messenger RNA carrying c.6881G\>A (p.Trp2294\*) would probably escape NMD and generate a protein lacking the six C-terminal residues, which may exert a dominant-negative effect. Of note, only one other reported *PTPRQ* mutation, homozygous c.6775delC in exon 44 in an autosomal-recessive inheritance nonsyndromic hearing loss family,^[@bib29]^ affects one of the two last exons. In contrast to the nonsense mutation discussed in our study, a protein generated from this frameshift mutation would be extremely elongated (p.Leu2259Serfs\*99), compatible with a recessive loss-of-function allele. We propose a genotype--phenotype correlation reminiscent of (throughout truncating) *DIAPH1* mutations causing dominant hearing loss only when located in a short stretch of the penultimate exon or its donor splice site,^[@bib30]^ and recessive disease if situated more N-terminally.^[@bib31]^

PTPRQ encodes protein tyrosine phosphatase receptor Q and has been found to be identical with the 275-kDa hair-cell antigen, a component of hair-bundle interstereocilial shaft connectors. As such, mouse Ptprq has been shown to be required for the maturation of the hair bundle.^[@bib28],\ [@bib32]^ *Ptprq* is downregulated in mice with a heterozygous or homozygous point mutation in the seed region of miR-96, a microRNA regulating several genes required for hearing and whose mutations are implicated in inherited hearing loss in mice and humans.^[@bib33],\ [@bib34]^ It is yet unknown if PTPRQ forms dimers, as has been shown for a related protein, PTPRO.^[@bib35]^ Interference with the normal protein deduced from the wild-type allele (dominant negative), but also the gain of a novel toxic function, are potential mechanisms of the assumingly autosomal-dominant C-terminal *PTPRQ* mutation reported herein. The loss of the C-terminal six amino acid residues could also prevent binding of intracellular interaction partners.

When assessing the potential pathogenicity of variants identified via NGS of a disease gene panel, variants in genes that have so far not been linked to the inheritance mode suspected in the given patient should also be considered. We therefore conducted segregation analysis for a heterozygous nonsense mutation in a recessive disease gene, *PTPRQ*, in a family with apparently dominant transmission of hearing loss. Based on current knowledge, this mutation could have been considered only as a carriership for a recessive mutation, and thus discarded without further verification. Additional WES and linkage analysis support the categorization of the C-terminal *PTPRQ* mutation as the disease-causing dominant mutation in this family; no other convincing candidate variant was identified, neither in NGS of the deafness gene panel nor in WES ([Table 1](#tbl1){ref-type="table"}, [Supplementary Table S3](#sup1){ref-type="supplementary-material"}), and importantly, the *PTPRQ* mutation is localized in the mapped chromosomal candidate region. Our findings indicate a "novel" mode of inheritance for *PTPRQ* mutations. Consequently, *PTPRQ* should be included in genetic diagnostic testing not only in patients with prelingual recessive deafness, but also in patients with hearing loss of variable age of onset and family history suggesting autosomal-dominant inheritance. Analogous to the apparent genotype--phenotype correlation in *DFNA1*, truncating mutations in the penultimate and in the last *PTPRQ* exon should receive special attention in that respect.

Patient IV:3 (4 years of age) carries the mutation and shows fluctuating results (from borderline to normal hearing) in audiologic assessment. However, considering the variable age of onset of the other *PTPRQ* mutation carriers in the family, he is likely to develop hearing impairment in the future. Our suggestion of *PTPRQ* as a candidate for autosomal-dominant hearing loss is strongly supported by the results of extensive genetic, but not protein, analyses. Analysis of protein function could further verify *PTPRQ* as an ADNSHL candidate gene, but would be complicated not only by the large size of the protein, but also because mutant PTPRQ~Trp2294\*~ would differ from the wild type by just six residues. We therefore quantified *PTPRQ* expression, and our findings support the hypothesis of a truncated "disease-causing" PTPRQ protein derived from the c.6881G\>A (p.Trp2294\*) transcript.

H.J.B. was supported by the GEERS-Stiftung. We thank the participating members of the family described herein for their support and cooperation, and Annika Greiche for excellent technical assistance.

[Supplementary material](#sup1){ref-type="supplementary-material"} is linked to the online version of the paper at http://www.nature.com/gim

The first two authors contributed equally to this work.

T.E., C.D., and C.N. are employees of Bioscientia, which is part of a publicly traded diagnostic company. H. J. B. was an employee of Bioscientia. The other authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![**Audiologic assessment.** Pure-tone audiometry for the right and left ear, index patient (in green) and selected affected family members.](gim2017155f1){#fig1}

![Genetic characterization of a German ADNSHL family segregating a PTPRQ nonsense mutation. (**a**) Pedigree of the ADNSHL family reported herein. Genotypes (M, p.Trp2294\*~*PTPRQ*~ mutation, WT, wild type) are given below the symbols. Whole-exome sequencing (WES) was conducted with the sample of IV:2. Green asterisks indicate family members whose samples were subjected to genome-wide linkage analysis. (**b**) Graphical view of the logarithm of the odds (LOD) score calculation from genome-wide single-nucleotide polymorphism mapping for the family: a LOD score of 2.1 was obtained for a region on chromosome 12 (12q21.2-12q22). (**c**) Electropherogram of the index patient. The nonsense mutation (red "STOP") is close to the natural termination codon (black "STOP") of the *PTPRQ* gene. (**d**) Graphical presentation of the candidate region from linkage analysis showing the contained genes. WES analysis did not reveal a clearly pathogenic aberration in any of these genes besides *PTPRQ*.](gim2017155f2){#fig2}

![PTPRQ protein and genomic structure and its analysis by NGS (gene panel and WES). (**a**) Scheme of the PTPRQ protein with protein domains (FN3, fibronectin type III repeats; TM, transmembrane domain; tyrosine PP, tyrosine protein phosphatase, with active site indicated). All Human Gene Mutation Database--listed mutations are indicated (localizations to scale; truncating mutations indicated above, missense mutations below the scheme). The C-terminal autosomal-dominant nonsyndromic hearing loss (ADNSHL)--associated nonsense mutation described herein is shown in red. (**b**) Coverage plots from NGS, both gene panel and whole-exome sequencing (WES), related to the *PTPRQ* RefSeq isoform NM_001145026.1. The 45 exons are completely covered in the panel setup. (**c**) Coverage plots from NGS, extended gene panel, and WES, related to all N-SCAN--predicted coding regions of a hypothetical "extended" fusion transcript including both *PTPRQ*, some interspersed exons, and the adjacent *OTOGL* gene, NM_173591.3. The red box highlights sequences that are not contained in NM_001145026.1, but which have been proposed as *PTPRQ* exons assigned by Schraders et al.^[@bib19]^](gim2017155f3){#fig3}

![**Semiquantitative reverse-transcription polymerase chain reaction (sqRT-PCR) for** ***PTPRQ*** **exons 2- and 45-spanning regions and quantification.** (**a**) sqRT-PCR of *PTPRQ* exon 2 and exon 45 region in control and patient-derived fibroblast cell lines. *ACTB* and *HPRT1* are used as reference genes. (**b**) Quantification of *PTPRQ* expression, normalized to the average of *ACTB* and *HPRT1*. There is no difference between the *PTPRQ* expression in the control and patient cell lines. Bars show the mean and standard errors. (**c**) Localization of primers related to the *PTPRQ* transcript.](gim2017155f4){#fig4}

###### Results from whole-exome sequencing of a sample of the index patient, IV:2

  **Gene**                                                                                                                     **Isoform**      **cDNA**       **Protein**    **Zygosity**   **rs ID**     **Clin. assoc.**   **Ref.**     **Funct. pred.**   **Cons. pred.**   **TGP AF (%)**   **ESP AF (%)**   **ExAC AF (%)**   **% Covered**
  ---------------------------------------------------------------------------------------------------------------------------- ---------------- -------------- -------------- -------------- ------------- ------------------ ------------ ------------------ ----------------- ---------------- ---------------- ----------------- ---------------
  *Filter 1: variants located in mapped candidate region on chromosome 12 (78,839,926 (rs10860423)--93,458,831 (rs1542481))*                                                                                                                                                                                                        
   *LRRIQ1*                                                                                                                    NM_001079910.1   c.4948delA     p.Met1650\*    het.           rs763597988   ---                ---          ---                ---               ---              ---              0.00083           88.40
   *PTPRQ*                                                                                                                     NM_001145026.1   c.6881G\>A     p.Trp2294\*    het.           ---           ---                ---          3/3                4/4               ---              ---              ---               94.42
   *SYT1*                                                                                                                      NM_005639.2      c.1258G\>A     p.Val420Ile    het.           rs61756211    ---                ---          1/10               2/6               ---              0.12             0.32 (1 × hom)    100.00
   *TMTC2*                                                                                                                     NM_152588.1      c.1141G\>A     p.Val381Ile    het.           rs35725509    ---                ---          1/10               1/6               1.16             0.55             1.12 (24 × hom)   98.88
  Filter 3: Variants in genes reportedly associated with hearing impairment (HGMD keywords: *hearing*, *deafness*)                                                                                                                                                                                                                  
   *PTPRQ*                                                                                                                     NM_001145026.1   c.6365G\>A     p.Trp2122\*    het.           ---           ---                ---          3/3                4/4               ---              ---              ---               94.42
   *COL9A3*                                                                                                                    NM_001853.3      c.1427C\>G     p.Pro476Arg    het.           rs142066316   ---                ---          7/10               6/6               0.16             0.3              0.18 (3 × hom)    93.75
   *RDX*                                                                                                                       NM_002906.3      c.1412C\>A     p.Pro471His    het.           rs754733997   ---                ---          4/10               6/6               ---              ---              0.00082           89.90
   *RDX*                                                                                                                       NM_002906.3      c.1557G\>C     p.Gln519His    het.           rs761349279   ---                ---          6/10               4/6               ---              ---              0.00082           89.90
   *MYH7B*                                                                                                                     NM_020884.4      c.772G\>A      p.Gly258Arg    het.           ---           ---                ---          5/10               6/6               ---              ---              ---               98.80
   *TSPEAR*                                                                                                                    NM_144991.2      c.88C\>T       p.Arg30Cys     het.           rs138759270   ---                ---          4/9                6/6               ---              0.05             0.02              100.00
   *LOXHD1*                                                                                                                    NM_144612.6      c.2575C\>T     p.Arg859Trp    het.           rs372546084   ---                ---          7/10               4/6               0.02             0.02             0.02              99.93
   *KCNE1*                                                                                                                     NM_000219.5      c.139G\>A      p.Val47Ile     het.           rs199473353   Yes                ---          1/7                1/6               0.1              ---              0.01              99.02
   *MYO15A*                                                                                                                    NM_016239.3      c.1111C\>A     p.Pro371Thr    het.           rs200382813   ---                ---          4/9                1/6               0.04             0.23             0.14              98.79
   *GJB2*                                                                                                                      NM_004004.5      c.109G\>A      p.Val37Ile     het.           rs72474224    Yes                ^[@bib36]^   5/10               4/6               1.54             0.13             0.66 (39 × hom)   94.86
   *PNKP*                                                                                                                      NM_007254.3      c.58C\>T       p.Pro20Ser     het.           rs3739168     ---                ^[@bib37]^   1/10               5/6               0.66             0.9              0.76 (6 × hom)    100.00
   *PNKP*                                                                                                                      NM_007254.3      c.1127-8C\>T   ---            het.           rs3739203     ---                ---          ---                ---               0.54             0.92             0.72 (7 × hom)    100.00
   *USH2A*                                                                                                                     NM_206933.2      c.688G\>A      p.Val230Met    het.           rs45500891    Yes                ^[@bib38]^   1/9                0/6               1.02             1.59             1.55 (18 × hom)   99.53
   *USH2A*                                                                                                                     NM_206933.2      c.7685T\>C     p.Val2562Ala   het.           rs56385601    Yes                ---          2/10               4/6               0.48             0.65             0.65 (8 × hom)    99.53
   *GJB3*                                                                                                                      NM_024009.2      c.94C\>T       p.Arg32Trp     het.           rs1805063     ---                ^[@bib39]^   9/10               5/6               1.3              2.31             2.42 (56 × hom)   100.00

AF, allele frequency; cDNA, complementary DNA; Clin. assoc., SNPs annotated as "clinically associated" covered, percentage of nucleotides of the gene that are covered at least 15 × ; Cons. pred., assessment of conservation by PhyloP, GERP++, PhastCons, SiPhy, Grantham Distance and BLOSUM62; ESP, Exome Sequencing Project; ExAC, Exome Aggregation Consortium; Funct. pred., functional predictions by SIFT, PolyPhen-2, MutationTaster, MutationAssessor, FATHMM, LRT, VEST, CADD, PROVEAN, and DANN; het, heterozygous; HGMD, Human Gene Mutation Database; hom, number of healthy ExAC individuals who are homozygous for the respective variant; Isoform, RefSeq accession number of the reported isoform; rs ID, rs number according to dbSNP build 144; TGP, 1000 Genomes Project.

The upper part (filter 1) lists variants, including the *PTPRQ* nonsense mutation, located in the chromosomal candidate region identified via genome-wide linkage analysis. filter 3 (lower part) analyzed for variants in genes knowingly associated with inherited hearing impairment.
